Evidence map›Paper›PMID 39099574›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2024

Screening for atrial fibrillation: the role of CHA

Lucas Yixi Xing, Oliver B Vad, Daniel Engler, Jesper H Svendsen, Søren Z Diederichsen

Abstract read
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Vascular cell adhesion molecule 1: a marker for atrial fibrillation and heart failure risk.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lucas Yixi XingDepartment of Cardiology, Heart Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-0184-3125
Oliver B VadDepartment of Cardiology, Heart Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-8416-0543
Daniel EnglerDepartment of Cardiology, University Heart and Vascular Center Hamburg Eppendorf, Hamburg, Germany.ORCID https://orcid.org/0000-0002-9519-6258
Jesper H SvendsenDepartment of Cardiology, Heart Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-8466-8515
Søren Z DiederichsenDepartment of Cardiology, Heart Center, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-9687-0857

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individuals with subclinical atrial fibrillation (AF) face an increased risk of thromboembolic events, which may potentially be mitigated through AF screening and subsequent anticoagulation. However, data from randomized clinical trials (RCTs) indicate a lower stroke risk in subclinical AF compared with the clinical phenotype. This-along with the inherent bleeding risk related to anticoagulation-seems to render the net clinical benefit of AF screening less evident. Further, current guidelines recommend consideration of CHA

Indexed as

AnticoagulationAtrial fibrillationScreeningStroke

Identifiers

PMID39099574
PMCPMC11292411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.